NEW YORK – Germany-based immuno-oncology company Affimed today announced that it had successfully dosed its first patient with AFM24, an EGFR- and CD16A-binding innate cell engager therapy.
The news marks the start of the company's Phase I/IIb trial of AFM24 in adult patients with EGFR-positive advanced solid tumors. The open-label, non-randomized, multi-center study will assess the maximum tolerated dose of AFM24 as a monotherapy in patients whose disease has progressed after previous lines of treatment, as well as gather preliminary evidence on safety and efficacy.